Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Critical Reviews™ in Eukaryotic Gene Expression

 

ISSN for PRINT: 1045-4403

Institutional price:

$708.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2003, Volume13

Issue 2-4

  227 pages  

DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24   

click 'Save as...' here to save XML metadata

Issue price - $507.00  

Add to shopping cart

  • In Vitro Studies with the Calcimimetic, Cinacalcet HCl, on Normal Human Adult Osteoblastic and Osteoclastic Cells
  • Victoria Shalhoub
    Department of Metabolic Disorders, 14-1-D, 1 Amgen Center Dr., Thousand Oaks, CA 91320

    Mario Grisanti
    Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA 91320

    Jen Padagas
    Hematology Department, Amgen, Inc., Thousand Oaks, CA 91320

    Sheila Scully
    Pathology Department, Amgen, Inc., Thousand Oaks, CA 91320

    Alana Rattan
    Pathology Department, Amgen, Inc., Thousand Oaks, CA 91320

    Meiying Qi
    Pathology Department, Amgen, Inc., Thousand Oaks, CA 91320

    Brian Varnum
    Inflammation Department, Amgen, Inc., Thousand Oaks, CA 91320

    Chris Vezina
    Inflammation Department, Amgen, Inc., Thousand Oaks, CA 91320

    David Lacey
    Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA 91320

    David Martin
    Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA 91320


    ABSTRACT

    This study examined whether the calcium-sensing receptor (CaR) is expressed in normal adult human osteoblastic and osteoclastic cells in culture, and whether the calcimimetic, cinacalcet HCl (AMG 073), potentiates the effects of calcium (via CaR, or some other receptor/mechanism). When mouse or human osteoblastic cells were treated with higher concentrations of calcium (6.6 or 8.6 mM in a-MEM/10% FBS) than present in control cultures (1.6 mM), the previously well-documented increase in cell number was demonstrated. Cinacalcet HCl affected cell proliferation of CHO cells transfected with CaR, dose dependently, but had no effect on human or mouse osteoblastic cell proliferation in calcium-containing medium (1.6 or 8.6 mM). To test cinacalcet HCl and calcium on osteoclastic cells, peripheral blood mononuclear cells were cultured in medium containing RANK ligand and M-CSF, supplemented with calcium, and/or cinacalcet HCl. Tartrate-resistant acid phosphatase–positive multinucleated osteoclastic cells on plastic or bone were then counted at 11 and 21 days, respectively. Calcium (greater than 6.0 mM) inhibited osteoclast formation, but cinacalcet HCl (30–1000 nM) had no effect on osteoclastic formation or resorption in the presence of calcium (1.6 or 6.1 mM). RT-PCR did not detect CaR in human, rat, or mouse primary osteoblastic cells and cell lines or osteoclastic cells. In conclusion, these studies indicate that the calcium-induced increase in osteoblastic cell number, and the decrease in formation/function of osteoclastic cells, involves a mechanism or receptor other than CaR. In addition, the calcimimetic agent did not potentiate the effects of calcium on normal adult human bone cells in vitro.

    DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.30

    Download article, 18 pages

    Article price - $35.00  

    Add to shopping cart

    << Previous article   Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com